Biogen ( NASDAQ:BIIB ) has received a significant boost with the Food and Drug Administration's accelerated approval for Qalsody, a drug aimed at treating ALS, a debilitating muscle-wasting disease. While the approval marks a significant milestone in Biogen's efforts to address critical medical needs, the company faces challenges amidst concerns over its earnings...
Looking at the options chain today, i would buy the $255 calls with
2022-9-16 expiration date for about
$3.40 premium.
Looking forward to read your opinion about it.
BIIB has broken out of triangle triangle formation on strong signals from super guppy and MACD indicators. I expect this breakout to continue on both its solid technical's as well as the strong sentiment in regards to BIIB's potential ceiling. Two crucial stories to watch going forward are the potential appeals court reversal related to their multiple sclerosis...
An intermediate-term basing bottom created by Dark Pool Quiet Accumulation completed with a High Frequency Trader gap up to a resistance level recently. BIIB retraced due to Pro Traders taking profits.
Biogen has lost over 30% of its value this month. Looking at the monthly chart, we have concluded that this is a rare investment opportunity as the current price is just above its 1M Support Zone.
Historically we see that such an aggressive sell off recently took place in 2015 - 2016 and again the stock managed to recover almost reaching the 390 Resistance...
